Plazomicin Market
The market for Plazomicin was estimated at $478 million in 2024; it is anticipated to increase to $697 million by 2030, with projections indicating growth to around $956 million by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Plazomicin Market Outlook
Revenue, 2024
$478M
Forecast, 2034
$897M
CAGR, 2025 - 2034
6.5%
The Plazomicin industry revenue is expected to be around $509.0 million in 2025 and expected to showcase growth with 6.5% CAGR between 2025 and 2034. The market is gaining strategic importance due to the rising global burden of multidrug-resistant bacterial infections and the increasing need for advanced antibacterial therapies in hospital settings. Growing concerns regarding antimicrobial resistance, coupled with higher hospitalization rates associated with severe urinary tract and bloodstream infections, are strengthening demand for effective next-generation antibiotics. Healthcare providers and pharmaceutical companies are also focusing on expanding antimicrobial stewardship programs and improving infection management outcomes, further supporting the ongoing commercial relevance of plazomicin within the evolving anti-infective therapeutics landscape.
Plazomicin is a next-generation aminoglycoside antibiotic primarily used for the treatment of complicated urinary tract infections caused by resistant gram-negative bacteria. The drug is designed to address antimicrobial resistance challenges by providing enhanced activity against difficult-to-treat bacterial pathogens commonly associated with hospital-acquired infections. Major applications are concentrated in hospitals, critical care units, infectious disease treatment programs, and specialty healthcare facilities managing severe bacterial infections. Recent trends driving demand include increasing prevalence of antibiotic-resistant infections, growing investments in advanced antibacterial drug development, and expanding global focus on infection control initiatives. Pharmaceutical companies are also pursuing strategic collaborations, regulatory expansion activities, and antimicrobial research programs to strengthen product adoption and improve treatment accessibility across developed and emerging healthcare markets.
Market Key Insights
The Plazomicin market is projected to grow from $478.0 million in 2024 to $897 million in 2034. This represents a CAGR of 6.5%, reflecting rising demand across Complicated Urinary Tract Infections and Management of Bloodstream Infections.
Achaogen Inc., Johnson & Johnson, Merck & Co. are among the leading players in this market, shaping its competitive landscape.
U.S. and Germany are the top markets within the Plazomicin market and are expected to observe the growth CAGR of 4.2% to 6.2% between 2024 and 2030.
Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 7.5% to 9.0%.
Transition like Transition from Broad-Spectrum Antibiotics Toward Targeted Resistant Infection Therapies has greater influence in United States and Germany market's value chain; and is expected to add $18 million of additional value to Plazomicin industry revenue by 2030.
The Plazomicin market is set to add $419 million between 2024 and 2034, with manufacturer targeting Clinics & Specialty Pharmacies Application projected to gain a larger market share.
With
expanding antimicrobial resistance, and
Pervasive Need in Complex Urinary Tract Infections, Plazomicin market to expand 88% between 2024 and 2034.
Opportunities in the Plazomicin
Rising incidence of multidrug resistant bacterial infections is generating significant opportunities for plazomicin manufacturers worldwide. Hospitals and infectious disease specialists are increasingly prioritizing advanced aminoglycoside therapies for complicated urinary tract infections and severe healthcare associated bacterial outbreaks. Critical care applications in Europe and Asia Pacific are expected to experience substantial demand growth due to increasing antimicrobial resistance concerns and expanding hospital infection management programs. Technological advancements in bacterial susceptibility testing and precision infectious disease diagnostics are improving treatment optimization. Strategic partnerships between pharmaceutical companies and healthcare organizations are also strengthening commercialization opportunities for targeted antibacterial therapies across emerging healthcare markets.
Growth Opportunities in North America and Asia Pacific
North America represents a leading region in the plazomicin market due to the high prevalence of multidrug-resistant bacterial infections, advanced healthcare infrastructure, and strong antimicrobial stewardship initiatives. The United States dominates regional demand as hospitals and critical care centers increasingly adopt advanced antibacterial therapies for complicated urinary tract and bloodstream infections caused by resistant gram-negative pathogens. Major opportunities are emerging in infectious disease treatment programs, hospital pharmacy networks, and critical care management services focused on improving patient outcomes. Competition remains strong among pharmaceutical companies developing next-generation antibiotics and resistant infection therapies. Rising healthcare investments, increasing hospitalization rates, and expanding infection control protocols continue to strengthen market growth. In addition, strategic collaborations between pharmaceutical manufacturers, hospital systems, and clinical research organizations are supporting wider adoption of plazomicin within specialized antimicrobial treatment programs across North America.
Asia Pacific is emerging as a significant growth region for the plazomicin market due to rising antimicrobial resistance cases, expanding hospital infrastructure, and increasing awareness regarding advanced infection management solutions. Countries such as China, India, Japan, and South Korea are witnessing growing demand for effective antibacterial therapies as healthcare systems address increasing rates of hospital-acquired infections and resistant bacterial outbreaks. Key opportunities exist within tertiary hospitals, infectious disease treatment centers, and government-supported antimicrobial control programs. Competition is intensifying as regional pharmaceutical firms and international antibiotic manufacturers strengthen distribution partnerships and expand anti-infective treatment portfolios. Government initiatives supporting antibiotic stewardship and healthcare modernization are further encouraging market development. Additionally, rising healthcare expenditure and growing investments in infectious disease diagnostics and hospital-based critical care services are expected to accelerate plazomicin adoption across Asia Pacific healthcare markets.
Market Dynamics and Supply Chain
01
Driver: Rising Antimicrobial Resistance Cases and Increasing Demand for Advanced Hospital Antibiotics
The growing prevalence of multidrug resistant bacterial infections is also a major factor driving the plazomicin market. Hospitals and infectious disease specialists are also increasingly seeking advanced aminoglycoside antibiotics capable of treating resistant gram negative bacterial infections that show limited response to conventional therapies. Rising incidence of complicated urinary tract infections and healthcare associated bacterial outbreaks is also strengthening demand for targeted antibacterial treatments in critical care settings. Simultaneously, increasing demand for advanced hospital antibiotics is also accelerating market growth. Healthcare systems are also investing in specialized antimicrobial stewardship programs and rapid bacterial diagnostic technologies to improve treatment precision and infection management outcomes. Pharmaceutical companies are also also expanding research into next generation antibacterial therapies to address the growing global burden of antimicrobial resistance and strengthen hospital based infectious disease treatment capabilities.
The increasing adoption of rapid bacterial diagnostic technologies is also significantly supporting growth in the plazomicin market. Healthcare providers are also utilizing advanced molecular diagnostics and automated pathogen identification systems to rapidly detect resistant bacterial strains and optimize targeted antibiotic therapy selection. Precision infectious disease management approaches are also improving treatment efficiency and reducing inappropriate antibiotic usage in hospital environments. In addition, advancements in clinical microbiology platforms and antimicrobial susceptibility testing technologies are also enabling faster identification of patients requiring specialized aminoglycoside therapies such as plazomicin. Growing investment in hospital laboratory modernization and infection surveillance systems is also further strengthening demand for advanced antibacterial treatments across critical care and infectious disease management sectors globally.
02
Restraint: Limited Commercial Adoption Due to Restricted Antibiotic Stewardship Prescribing Practices
One of the major restraints affecting the plazomicin market is the restricted prescribing environment created by strict antibiotic stewardship programs. Healthcare providers increasingly reserve advanced antibacterial therapies for severe multidrug resistant infections to reduce the risk of antimicrobial resistance development. As a result, plazomicin usage remains concentrated within specialized hospital settings and critical care environments rather than broad clinical applications. For example, infectious disease specialists may prioritize older lower cost antibiotics before utilizing premium aminoglycoside therapies. These prescribing limitations reduce prescription volumes, constrain market penetration, and create slower revenue expansion opportunities within the competitive antibacterial therapeutics industry.
03
Opportunity: Expanding Hospital Antimicrobial Stewardship Programs Across North American Critical Care Networks and Increasing Rapid Diagnostic Adoption Enhancing Precision Infectious Disease Treatment Strategies Worldwide
The expansion of antimicrobial stewardship programs across North American hospitals is creating strong opportunities for the plazomicin market. Healthcare institutions are increasingly adopting targeted antibacterial therapies to address multidrug resistant gram negative infections within intensive care and infectious disease treatment units. Intravenous aminoglycoside antibiotic formulations are expected to witness the highest growth across tertiary hospitals and specialized critical care centers. Rapid molecular diagnostic technologies and advanced infection surveillance systems are improving identification of resistant bacterial strains, supporting more precise antibiotic selection. The United States is anticipated to remain the leading regional market due to advanced healthcare infrastructure and strong investment in antimicrobial resistance management initiatives.
The growing adoption of rapid bacterial diagnostic platforms is creating favorable opportunities for plazomicin within precision infectious disease management applications. Healthcare providers are increasingly utilizing automated pathogen identification systems and molecular diagnostic technologies to detect resistant infections more efficiently and support targeted antibiotic selection. Hospital laboratories and specialized infectious disease centers in developed healthcare markets are expected to drive the strongest demand growth for advanced antibacterial therapies. Improvements in microbiology automation and antimicrobial resistance surveillance systems are accelerating integration of precision antibiotic treatment protocols. Increasing investment in hospital laboratory modernization and infection control infrastructure is further supporting long term market expansion opportunities for plazomicin globally.
04
Challenge: High Development Costs and Intense Generic Antibiotic Competition Limiting Market Growth
The plazomicin market faces significant restraint from high antibacterial drug development costs and strong competition from established generic antibiotics. Pharmaceutical companies investing in advanced antibacterial therapies encounter substantial research expenses, regulatory compliance costs, and limited commercial return potential compared to other therapeutic areas. At the same time, hospitals and healthcare systems often favor lower cost generic antibacterial treatments to manage budget constraints and procurement efficiency. For instance, public healthcare institutions may restrict use of premium antibiotics unless resistance cases are confirmed through laboratory diagnostics. These pricing pressures and competitive dynamics reduce profit margins, influence purchasing behavior, and limit broader commercial expansion for plazomicin manufacturers globally.
Supply Chain Landscape
1
Raw Material Procurement
BASFDuPont
2
Intermediates Production
Bayer HealthcareTeva Pharmaceutical Industries
3
API Production
PfizerAchaogen
4
End Product Formulation
AchaogenCipla
1
Raw Material Procurement
BASFDuPont
2
Intermediates Production
Bayer HealthcareTeva Pharmaceutical Industries
3
API Production
PfizerAchaogen
4
End Product Formulation
AchaogenCipla
Use Cases of Plazomicin in Complicated Urinary Tract Infections & Management of Bloodstream Infections
Complicated Urinary Tract Infections : Plazomicin is widely utilized in the treatment of complicated urinary tract infections, particularly those caused by multidrug-resistant gram-negative bacteria. Intravenous plazomicin formulations are primarily used in hospitals, specialty infectious disease centers, and critical care units where severe bacterial infections require rapid and targeted antimicrobial intervention. Healthcare providers prefer plazomicin due to its strong antibacterial activity against resistant pathogens and its effectiveness in patients with limited treatment alternatives. The therapy is commonly administered to hospitalized adults with recurrent or severe urinary tract infections associated with antimicrobial resistance. Rising prevalence of hospital-acquired infections and increasing concerns regarding antibiotic-resistant bacterial strains continue to support demand for plazomicin within advanced urinary infection management applications globally.
Management of Bloodstream Infections : Plazomicin is increasingly gaining relevance in the management of bloodstream infections caused by resistant bacterial pathogens, particularly within intensive care and hospital-based infectious disease treatment programs. Injectable aminoglycoside formulations are commonly utilized for critically ill patients requiring advanced antibacterial therapies capable of addressing severe systemic infections. Hospitals and specialized healthcare facilities are major end users due to the growing incidence of bloodstream infections associated with prolonged hospitalization and invasive medical procedures. The drug offers advantages in treating difficult-to-manage gram-negative bacterial infections where conventional antibiotics may demonstrate reduced effectiveness. Increasing investment in antimicrobial stewardship programs, rising awareness regarding resistant bloodstream infections, and expanding hospital infection control initiatives are contributing to growing clinical interest and market demand for plazomicin-based therapeutic applications.
Impact of Industry Transitions on the Plazomicin Market
As a core segment of the Pharmaceutical industry,
the Plazomicin market develops in line with broader industry shifts.
Over recent years, transitions such as Transition from Broad-Spectrum Antibiotics Toward Targeted Resistant Infection Therapies and Transition from Conventional Infection Management to Hospital-Based Antimicrobial Stewardship Programs have redefined priorities
across the Pharmaceutical sector,
influencing how the Plazomicin market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Transition from Broad-Spectrum Antibiotics Toward Targeted Resistant Infection Therapies
The plazomicin market is witnessing a transition from conventional broad-spectrum antibiotic usage toward targeted therapies designed for multidrug-resistant bacterial infections. Hospitals and infectious disease specialists are increasingly prioritizing advanced aminoglycoside antibiotics capable of addressing resistant gram-negative pathogens associated with complicated urinary tract and bloodstream infections. This shift is influencing associated industries such as hospital pharmacy services, antimicrobial diagnostics, and pharmaceutical research organizations. For example, healthcare providers are expanding antimicrobial stewardship programs while biotechnology companies are increasing investments in resistant infection treatment pipelines. The transition is also encouraging greater collaboration between diagnostic laboratories and pharmaceutical manufacturers to support precision-focused antibacterial treatment strategies.
02
Transition from Conventional Infection Management to Hospital-Based Antimicrobial Stewardship Programs
The industry is also transitioning toward structured antimicrobial stewardship programs aimed at improving antibiotic utilization and reducing resistance-related healthcare risks. Hospitals and critical care centers are increasingly implementing controlled prescribing frameworks supported by infectious disease specialists and advanced microbial testing services. This transition is driving demand for specialized antibacterial therapies such as plazomicin within high-risk healthcare environments managing severe resistant infections. Related industries including clinical diagnostics, hospital informatics, and infection surveillance technologies are benefiting from increased focus on optimized infection management systems. Pharmaceutical companies are also strengthening partnerships with healthcare institutions to improve antibiotic accessibility, clinical awareness, and treatment outcome monitoring within modern hospital care ecosystems.